Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Subjects aged 18 and over who have any of the following diseases~* primary Pulmonary Arterial Hypertension~* secondary Pulmonary Arterial Hypertension caused by connective tissue disease~* \[Phase IIb\] Pulmonary Arterial Hypertension caused by congenital heart disease(including Eisenmenger syndrome)~Exclusion Criteria:~* Subjects with pulmonary arterial hypertension caused by any etiology other than those specified in the inclusion criteria~* BMI(Body Mass Index) \< 18.5kg/m2~* Subjects with hypotension(SBP/DBP\<90/50mmHg) or uncontrolled hypertension(SBP/DBP\>170/100mmHg)~* Creatinine clearance ≤ 30mL/min~* History of non-arteritic anterior ischemic optic neuropathy(NAION)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- udenafil (Type: EXPERIMENTAL): 1. Phase IIa Experimental : Udenafil Dose 1, Dose 2~2. Phase IIb Experimental : Udenafil
- placebo (Type: PLACEBO_COMPARATOR): 1. Phase IIa Placebo Comparator : Placebo~2. Phase IIb Placebo Comparator : Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).